Company Overview

Cardio Diagnostics Holdings, Inc. is a U.S.-based precision cardiovascular medicine company focused on integrating artificial intelligence, epigenetics, and clinical diagnostics to improve the detection and management of cardiovascular disease. The company operates within the healthcare diagnostics, biotechnology, and digital health industries, with an emphasis on blood-based cardiovascular testing and personalized risk assessment. Its primary commercial offerings include epigenetic and genetic tests intended to assist clinicians in identifying coronary heart disease risk and supporting disease management strategies.

The company’s principal revenue drivers are laboratory-developed diagnostic tests, clinical partnerships, and commercialization of proprietary cardiovascular risk assessment technologies. Key customer segments include healthcare providers, physician groups, hospitals, and preventative medicine practices. Cardio Diagnostics positions itself as a precision medicine company leveraging machine learning-enabled biomarker analysis to deliver non-invasive cardiovascular diagnostics. The company was founded in 2017 and later became publicly traded through a merger transaction involving a special purpose acquisition company. Public disclosures in SEC filings and investor materials indicate that the company has evolved from a research-oriented diagnostics developer into a commercially focused cardiovascular testing enterprise centered on AI-driven precision medicine.

Business Operations

Cardio Diagnostics conducts operations primarily through its diagnostic testing and precision cardiovascular analytics platform. Its core offerings include the Epi+Gen CHD test, designed to assess symptomatic coronary heart disease risk, and the PrecisionCHD test, aimed at evaluating the likelihood of future coronary heart disease in asymptomatic individuals. The company generates revenue through test commercialization, laboratory services, and strategic healthcare relationships. Operations are concentrated in the United States, where the company manages research, product development, and commercialization activities.

The company’s operational model relies on proprietary epigenetic-genetic biomarker databases, machine learning algorithms, and clinical analytics capabilities. Public disclosures indicate that Cardio Diagnostics controls intellectual property associated with its integrated epigenetic and genetic cardiovascular testing methodologies. The company has also pursued collaborations with healthcare providers and industry participants to support clinical adoption and validation efforts. Based on publicly available information, no large-scale international joint ventures or diversified operating subsidiaries have been prominently disclosed in recent filings. Data regarding material foreign operating units is inconclusive based on available public sources.

Strategic Position & Investments

Cardio Diagnostics’ strategic direction centers on expanding adoption of AI-powered cardiovascular diagnostics and strengthening its role in preventative healthcare and precision medicine. Growth initiatives disclosed in company filings and investor communications include commercialization expansion, physician network development, reimbursement advancement efforts, and continued clinical validation studies. The company has also emphasized increasing awareness of cardiovascular disease screening through digital health integration and population health applications.

The company’s investment focus has been concentrated on research and development, intellectual property expansion, and enhancement of its machine learning-driven diagnostic platform. Cardio Diagnostics has highlighted the importance of integrating epigenetic science with AI analytics to differentiate its testing solutions from conventional cardiovascular screening tools. Public records indicate ongoing investment in proprietary datasets and software-enabled diagnostic capabilities rather than large acquisition-driven growth. No major acquisitions comparable to large-cap healthcare consolidations were identified in reviewed public disclosures. Emerging technology exposure includes artificial intelligence in healthcare diagnostics, precision medicine applications, and epigenetic biomarker analytics.

Geographic Footprint

Cardio Diagnostics is headquartered in Chicago, Illinois, and its primary commercial and operational activities are concentrated within the United States healthcare market. The company’s clinical and commercialization efforts are focused mainly on U.S.-based providers, diagnostic partnerships, and cardiovascular care networks. Public filings identify the United States as the company’s principal market and operational jurisdiction.

Although the company’s technology platform and intellectual property may have broader applicability across international healthcare systems, publicly available disclosures do not indicate substantial direct operational infrastructure outside the United States. Market visibility and commercialization activities appear predominantly domestic, with limited evidence of material international revenue contributions or foreign operating divisions. Data regarding significant overseas operational influence is inconclusive based on available public sources.

Leadership & Governance

Cardio Diagnostics was co-founded by Meesha Dogan, Ph.D., who has played a central role in shaping the company’s precision medicine and AI-focused strategy. Leadership communications and public filings emphasize a mission centered on improving early cardiovascular disease detection through data-driven diagnostics, preventative medicine, and personalized healthcare solutions. The company’s governance structure follows the standard framework of a publicly traded U.S. healthcare company, with executive leadership overseeing commercialization, scientific development, finance, and corporate operations.

Key executives identified in recent public disclosures include:

• Meesha Dogan, Ph.D. – Co-Founder and Chief Executive Officer
• Elliot Roth – Chief Financial Officer
• Robert Philibert, M.D., Ph.D. – Chief Medical Officer
• Mikhail Torosyan – Chief Operating Officer

The company’s leadership strategy has consistently emphasized innovation in AI-enabled diagnostics, expansion of clinical adoption pathways, and development of scalable precision cardiovascular testing technologies, as reflected in company presentations, earnings communications, and SEC filings.